Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18852 | 0.69 | NPC1 (0.34) | — | |
| SCHEMBL154513 | 0.67 | ALOX5 (0.39) | — | |
| SCHEMBL30931514 | 0.67 | CA12 (0.31) | CA12CA1CA2CA9 | |
| SCHEMBL9099992 | 0.67 | CA12 (0.31) | CA12CA1CA2CA9 | |
| SCHEMBL2035350 | 0.67 | CA12 (0.31) | CA12CA1CA2CA9 | |
| SCHEMBL16427955 | 0.64 | CYP1A2 (0.39) | CA12CA1CA2CA9 | |
| SCHEMBL15226257 | 0.61 | GSK3B (0.34) | CA12CA1CA2CA9 | |
| SCHEMBL16430005 | 0.61 | CA12 (0.30) | CA12CA1CA2CA9 | |
| SCHEMBL28783640 | 0.61 | — | — | |
| SCHEMBL3668283 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-10-29 | — | — | US | claimed |
| EP-2061751-A1 | NITRATE ESTERS OF AMINOALCOHOLS | Novartis Ag (CH) | 2009-05-27 | — | — | EP | claimed |
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | claimed |
| EP-2018862-A1 | Substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2009-01-28 | — | — | EP | claimed |
| WO-2008031811-A1 | NITRATE ESTERS OF AMINOALCOHOLS | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-20 | — | — | WO | claimed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | claimed |
| US-10201531-B2 | Indazolyl-oxo-isothiazole compounds | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | HEROLD PETER (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2291351-A1 | ALPHA-MERCAPTO-AMIDES | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20110009399-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| US-20100256146-A1 | TRISUBSTITUTED PIPERIDINES | NOVARTIS AG | 2010-10-07 | — | — | US | disclosed |
| EP-2163245-A1 | Renin inhibitors for the treatment of psoriasis | Novartis Ag (CH) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009135526-A1 | ALPHA-MERCAPTO-AMIDES | NOVARTIS AG (CH) | 2009-11-12 | — | — | WO | disclosed |
| WO-2008031811-A1 | NITRATE ESTERS OF AMINOALCOHOLS | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008017685-A1 | NITRATE ESTERS OF PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007141318-A1 | 2,5-DISUBSTITUTED PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-12-13 | — | — | WO | disclosed |
| EP-1863763-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1816122-A2 | 3,4,5-substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| WO-2006103275-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | CA12 4065/4885CA1 1025/4885CA2 754/4885 |
| US-20110009399-A1 | ORGANIC COMPOUNDS | REN, ACE, AGTR1 | CA12 4090/4885CA1 3823/4885CA2 725/4885 |
| US-10201531-B2 | Indazolyl-oxo-isothiazole compounds | KEAP1, NFE2L2, NQO1 | CA12 4693/4885CA1 4577/4885CA2 2191/4885 |
| US-20120115859-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | REN, AGTR1, AGTR2 | CA12 4721/4885CA1 4093/4885CA2 640/4885 |
| US-20090270380-A1 | 3,4,5-Substituted Piperidines as Renin Inhibitors | REN, AGTR1, AGTR2 | CA12 4730/4885CA1 4089/4885CA2 704/4885 |
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | REN, AGTR2, ACE | CA12 4640/4885CA1 4556/4885CA2 831/4885 |
| US-20100256146-A1 | TRISUBSTITUTED PIPERIDINES | REN, AGTR1, AGTR2 | CA12 4627/4885CA1 3762/4885CA2 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.